Related Experiment Video

Updated: May 7, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

Pak and Rac GTPases promote oncogenic KIT-induced neoplasms

Holly Martin, Raghuveer Singh Mali, Peilin Ma

    The Journal of Clinical Investigation
    |October 5, 2013
    PubMed

    Insights

    Targeting specific proteins like Vav1, Rac, and Pak can inhibit the growth of KIT-driven leukemic cells. This discovery offers new therapeutic strategies for systemic mastocytosis and acute myeloid leukemia (AML).

    Area of Science:

    • Oncology
    • Molecular Biology
    • Hematology

    Background:

    • Acquired somatic mutations in KIT codon 816 are linked to poor prognosis in systemic mastocytosis and acute myeloid leukemia (AML).
    • The p21-activated kinase (Pak) pathway is implicated in the growth of leukemic cells with KIT mutations.

    Purpose of the Study:

    • To investigate the role of Rac GTPases and their regulators, particularly Vav1, in KIT-driven leukemogenesis.
    • To evaluate the therapeutic potential of targeting the Rac-Pak pathway in myeloproliferative neoplasms (MPNs) and AML.

    Main Methods:

    • Utilized genetic inactivation and pharmacological inhibition (EHop-016) of Pak, Rac, and Vav1.
    • Assessed the impact on leukemic cell growth, apoptosis, and in vivo disease progression in mouse models.
    • Investigated the activation status of Rac1 and Rac2 via the guanine nucleotide exchange factor (GEF) Vav1.

    Main Results:

    • Inhibition or genetic inactivation of Pak or Rac led to growth repression and enhanced apoptosis in KIT-mutated leukemic cells.
    • Combined loss of Rac1 and Rac2 significantly repressed leukemic cell growth (75%).
    • Inhibition of Vav, Rac, or Pak in vivo delayed MPN onset and corrected associated pathology in mice.
    • EHop-016, a Vav1-specific inhibitor, potently inhibited human and murine leukemic cell growth.

    Conclusions:

    • Pak and Rac GTPases, including Vav1, are crucial for KIT-driven leukemic cell growth and oncogenic transformation.
    • Targeting Vav1, Rac, or Pak represents a promising therapeutic strategy for MPNs and AML with oncogenic KIT mutations.

    More Related Videos

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

    Published on: July 17, 2019

    Related Concept Videos

    Small GTPases - Ras and Rho01:24

    Small GTPases - Ras and Rho

    Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
    Three regulatory proteins control their activity:
    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a superfamily...
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...